作为具有抗炎作用的选择性二基化酶4抑制剂的利科卡尔康A衍生物
Ci-Qin Li1, Jin-Hui Shi1,2, Jie Mu1
1Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Journal of natural products
|June 20, 2023
概括
研究人员开发了22种利科哈尔科恩A类型作为二二酶4 (DPP4) 抑制剂. 化合物27显示出强大的DPP4抑制和抗炎作用,对正常细胞没有毒性.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 滴基酶4 (DPP4) 是治疗2型糖尿病的目标.
- 利科哈尔康A类型提供潜在的治疗途径.
- 探索具有抗炎性能的新型DPP4抑制剂至关重要.
研究的目的:
- 设计和合成利科卡尔A类型作为潜在的DPP4抑制剂.
- 为了评估这些类型的抗炎作用.
- 为了确定DPP4抑制的结构-活性关系.
主要方法:
- 合成22种利科哈尔康A类型的类似物.
- 使用光基质 (GP-BAN) 进行反DPP4活性体外评估.
- 结构-活性关系 (SAR) 分析,选择性分析,细胞毒性测定和基于细胞的测定.
主要成果:
- 化合物27是一种替代模拟物,表现出最强大的DPP4抑制 (Ki = 0.96μM).
- 4-基和5-替代剂对于DPP4抑制至关重要;3'-基提高了功效和稳定性.
- 化合物27对DPP4比其他蛋白酶具有选择性,对正常细胞有低毒性,同时抑制炎症化学因子.
结论:
- 化合物27是一种强效和选择性的DPP4抑制剂,具有显著的抗炎功能.
- 鉴定的结构特征是优化DPP4抑制活性的关键.
- 这项研究为开发新型抗糖尿病和抗炎药物提供了有希望的化合物.
更多相关视频
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Glucagon-like Receptor Agonists
369
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
369
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
218
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
218
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202


